Skip to content

Utah Study Evaluating Apneic Oxygenation for Emergency Department Intubation

Utah Study Evaluating Apneic Oxygenation for Emergency Department Intubation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02961933
Acronym
USE AP OX
Enrollment
500
Registered
2016-11-11
Start date
2016-12-31
Completion date
2020-06-30
Last updated
2020-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intubation

Keywords

hypoxemia, intubation, apneic oxygenation

Brief summary

This study will determine rates of first pass success without hypoxemia in emergency department intubations with and without the use of apneic oxygenation by nasal cannula.

Interventions

Nasal cannula apneic oxygenation

OTHERPre-oxgenation with NRB, NIPPV, BVM

Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask

Sponsors

University of Utah
CollaboratorOTHER
Intermountain Health Care, Inc.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Patients requiring emergent Rapid Sequence or Delayed Sequence endotracheal intubation with administration of a neuromuscular blocker (Succinylcholine, Rocuronium)

Exclusion criteria

* Known prisoners * Patients in cardiac arrest * Patients who are intubated without the use of neuromuscular blockade (i.e., cardiac arrest, awake intubation).

Design outcomes

Primary

MeasureTime frame
First pass success without hypoxemia10 minutes

Secondary

MeasureTime frame
Change in peri-intubation saturation0, 30, 60 and 120 seconds
Saturation at time of tube placement10 minutes
Time to desaturation <93%measured time until saturations drop below 93% during the peri-intubation period, up to 10 minutes
Saturation at post intubation0, 30, 60, and 120 seconds

Countries

United States

Contacts

Primary ContactValerie Aston, MBA, RT
valerie.aston@imail.org801-507-4606

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026